SecProbe.io

<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>corresp_sep172004.txt
<TEXT>
                                     CORRESP

                                                           Nova Biogenetics Inc.
                                                            8601 Dunwoody Place.
                                                                       Suite 338
                                                               Atlanta, GA 30350
                                                                Ph: 770-650-6508
                                                               Fax: 770-650-0411

September 17, 2004

Cicely Luckey
Senior Staff Accountant
Division of Corporation Finance
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

Re:      Nova Biogenetics, Inc. ("Nova")
         Item 4 Form 8-K filed September 2, 2004
         Commission Comment Letter dated September 3, 2004

Dear Ms. Luckey:

In connection with Commission Comments contained in its above-referenced
September 3, 2004 letter, we are writing so as to acknowledge that: (i) Nova is
responsible for the adequacy and accuracy of the disclosure in its filings; (ii)
staff comments or changes to disclosure in response to staff comments in the
filings reviewed by the staff do not foreclose the Commission from taking any
action with respect to the filing; and (iii) Nova may not assert staff comments
as a defense in any proceeding initiated by the Commission or any person under
the federal securities laws of the United States.

Very truly yours,

NOVA BIOGENETICS, INC.

Kevin Smith
Chief Executive Officer

</TEXT>
</DOCUMENT>